Our findings were consistent with those of a recent study, which also revealed that HER2(3+) BC patients displayed significantly higher pCR rates compared with HER2(2+)/FISH-positive BC patients after dual-target NAT (41.7% vs. 63.3%, P=0.017) (19). This evidence concerns the gene ERBB2 and breast cancer.